These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 27499157)

  • 21. Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: lipiodol vs. drug-eluting beads.
    Guiu B; Deschamps F; Aho S; Munck F; Dromain C; Boige V; Malka D; Leboulleux S; Ducreux M; Schlumberger M; Baudin E; de Baere T
    J Hepatol; 2012 Mar; 56(3):609-17. PubMed ID: 22027582
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Doxorubicin-loaded drug-eluting beads versus conventional transarterial chemoembolization for nonresectable hepatocellular carcinoma.
    Arabi M; BenMousa A; Bzeizi K; Garad F; Ahmed I; Al-Otaibi M
    Saudi J Gastroenterol; 2015; 21(3):175-80. PubMed ID: 26021777
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma].
    Ferrer Puchol MD; la Parra C; Esteban E; Vaño M; Forment M; Vera A; Cosín O
    Radiologia; 2011; 53(3):246-53. PubMed ID: 21295802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transarterial chemoembolization with drug-eluting beads in hepatocellular carcinoma: usefulness of contrast saturation features on cone-beam computed tomography imaging for predicting short-term tumor response.
    Suk Oh J; Jong Chun H; Gil Choi B; Giu Lee H
    J Vasc Interv Radiol; 2013 Apr; 24(4):483-9. PubMed ID: 23452553
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and feasibility of same-day discharge of patients with unresectable hepatocellular carcinoma treated with doxorubicin drug-eluting bead transcatheter chemoembolization.
    Prajapati HJ; Rafi S; El-Rayes BF; Kauh JS; Kooby DA; Kim HS
    J Vasc Interv Radiol; 2012 Oct; 23(10):1286-93.e1. PubMed ID: 22999748
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Superselective Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma: Rationale, Technique, and Outcome.
    Miyayama S; Matsui O
    J Vasc Interv Radiol; 2016 Sep; 27(9):1269-1278. PubMed ID: 27345337
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comprehensive Analysis of Factors Affecting Clinical Response and Short-Term Survival to Drug-Eluting Bead Transarterial Chemoembolization for Treatment in Patients With Liver Cancer.
    Wu X; Chen R; Zheng W; Hu H
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818759878. PubMed ID: 29739274
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.
    Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J
    J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Superselective Chemoembolization of HCC: Comparison of Short-term Safety and Efficacy between Drug-eluting LC Beads, QuadraSpheres, and Conventional Ethiodized Oil Emulsion.
    Duan F; Wang EQ; Lam MG; Abdelmaksoud MH; Louie JD; Hwang GL; Kothary N; Kuo WT; Hofmann LV; Sze DY
    Radiology; 2016 Feb; 278(2):612-21. PubMed ID: 26334787
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Single-Center Retrospective Comparison of Doxorubicin-Loaded HepaSphere Transarterial Chemoembolization with Conventional Transarterial Chemoembolization for Patients with Unresectable Hepatocellular Carcinoma.
    Kucukay F; Badem S; Karan A; Ozdemir M; Okten RS; Ozbulbul NI; Kucukay MB; Unlu I; Bostanci EB; Akdogan M
    J Vasc Interv Radiol; 2015 Nov; 26(11):1622-9. PubMed ID: 26321015
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study.
    Xing M; Webber G; Prajapati HJ; Chen Z; El-Rayes B; Spivey JR; Pillai AA; Kim HS
    J Gastroenterol Hepatol; 2015 Jul; 30(7):1167-74. PubMed ID: 25675849
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemoembolization and bland embolization of neuroendocrine tumor metastases to the liver.
    Ruutiainen AT; Soulen MC; Tuite CM; Clark TW; Mondschein JI; Stavropoulos SW; Trerotola SO
    J Vasc Interv Radiol; 2007 Jul; 18(7):847-55. PubMed ID: 17609443
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Conventional Ethiodized Oil Transarterial Chemoembolization for Treatment of Hepatocellular Carcinoma: Contemporary Single-Center Review of Clinical Outcomes.
    Casadaban LC; Minocha J; Bui JT; Knuttinen MG; Ray CE; Gaba RC
    AJR Am J Roentgenol; 2016 Mar; 206(3):645-54. PubMed ID: 26901023
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acute pancreatitis induced by transarterial chemoembolization: a single-center experience of over 1500 cases.
    She WH; Chan AC; Cheung TT; Chok KSh; Chan SC; Poon RT; Lo CM
    Hepatobiliary Pancreat Dis Int; 2016 Feb; 15(1):93-8. PubMed ID: 26818549
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predicting Treatment Response to Intra-arterial Therapies for Hepatocellular Carcinoma with the Use of Supervised Machine Learning-An Artificial Intelligence Concept.
    Abajian A; Murali N; Savic LJ; Laage-Gaupp FM; Nezami N; Duncan JS; Schlachter T; Lin M; Geschwind JF; Chapiro J
    J Vasc Interv Radiol; 2018 Jun; 29(6):850-857.e1. PubMed ID: 29548875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liver and biliary damages following transarterial chemoembolization of hepatocellular carcinoma: comparison between drug-eluting beads and lipiodol emulsion.
    Monier A; Guiu B; Duran R; Aho S; Bize P; Deltenre P; Dunet V; Denys A
    Eur Radiol; 2017 Apr; 27(4):1431-1439. PubMed ID: 27436016
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CalliSpheres® drug-eluting beads (DEB) transarterial chemoembolization (TACE) is equally efficient and safe in liver cancer patients with different times of previous conventional TACE treatments: a result from CTILC study.
    Zhang X; Zhou J; Zhu DD; Huang J; Sun JH; Li TF; Shi CS; Sun ZC; Hou QM; Peng ZY; Yu WQ; Ji JS; Gu WJ; Zhou GH; Xie XX; Guo XH; Cao GH; Yu ZH; Xu HH; Fang J; Ying SH; Hu WH; Ji WB; Han J; Wu X; Zheng JP; Luo J; Chen YT; Hu TY; Li L; Hu HJ; Du HJ; Shao GL
    Clin Transl Oncol; 2019 Feb; 21(2):167-177. PubMed ID: 30003530
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemoembolization of hepatocellular carcinoma with HepaSphere 30-60 μm. Safety and efficacy study.
    Malagari K; Pomoni M; Moschouris H; Kelekis A; Charokopakis A; Bouma E; Spyridopoulos T; Chatziioannou A; Sotirchos V; Karampelas T; Tamvakopoulos C; Filippiadis D; Karagiannis E; Marinis A; Koskinas J; Kelekis DA
    Cardiovasc Intervent Radiol; 2014 Feb; 37(1):165-75. PubMed ID: 24263774
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimal measurement modality and method for evaluation of responses to transarterial chemoembolization of hepatocellular carcinoma based on enhancement criteria.
    Shim JH; Han S; Shin YM; Yu E; Park W; Kim KM; Lim YS; Lee HC
    J Vasc Interv Radiol; 2013 Mar; 24(3):316-25. PubMed ID: 23312990
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver (RETNET): study protocol for a randomized controlled trial.
    Chen JX; Wileyto EP; Soulen MC
    Trials; 2018 Jul; 19(1):390. PubMed ID: 30016989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.